A 60-year-old woman with a history of hypertension, type II diabetes, and hyperlipidemia underwent her first cycle of intravenous chemotherapy with paclitaxel for endometrial clearcell adenocarcinoma at a standard rate of 135 mg/m 2 over 3 hours (body surface area 2.10 m 2 ).
obstructive coronary disease. Her oncologist was informed of the results, and an alternative chemotherapy regimen was chosen. At 1-week follow-up, she reported no recurrence of symptoms; repeat electrocardiogram displayed resolution of her LBBB (Fig. 2) .
LBBB results when the normal activation sequence in the His-Purkinje system is interrupted, with asynchronous and delayed activation of the left ventricle. 1 In most cases, LBBB is associated with underlying conduction system disease, which can be progressive. Multiple chronic conditions that promote myocardial fibrosis, such as hypertension, atherosclerosis, and valvular disease, can contribute to the gradual development of LBBB. However, there are some clinical scenarios, with acute coronary syndromes being the most commonly invoked, in which LBBB presents in a rather acute or subacute manner, leading to different diagnostic considerations ( Table 1) .
Paclitaxel is a natural product, originally isolated from the Pacific yew tree (Taxus brevipholia) that exhibits antineoplastic activity by inhibition of tubular polymerization. In early clinical trials, major hypersensitivity reactions were reported with the use of paclitaxel; 2 such reactions led to routine telemetry monitoring during subsequent phases, which unveiled previously unnoticed cardiovascular manifestations. Most of these are related to asymptomatic sinus tachycardia. 3 More serious cardiovascular events are rare but include hypotension, varying degrees of atrioventricular (AV) block, ventricular tachycardia, and acute coronary syndromes. 4, 5 Left bundle branch block has been reported with a frequency of 4%. 2 From a clinical standpoint, symptoms such as wheezing, dizziness, and rash have been described in the setting of hypersensitivity reactions to paclitaxel, but chest pain has been reported only in rare occasions. 6 The concomitant presence of chest discomfort and a new LBBB with the use of paclitaxel has not been previously described in the literature. Such presentation raised suspicion of an acute coronary syndrome and hence motivated the transfer of care of our patient.
The mechanism by which paclitaxel induces LBBB is not entirely clear, but the absence of other dynamic ischemic changes on the electrocardiogram and most importantly no evidence of myocardial Transient, several long R-R intervals followed by short R-R cycles, disappears at lower heart rates injury as measured by troponin levels, which very strongly suggests a nonischemic process, as myocardial contractility is not significantly dependent on microtubular function. Conversely, the sarcoplasmic and sarcotubular systems have important roles in electrical impulse conduction in the sinoatrial and atrioventricular nodes, as well as the His-Purkinje system, 7 which would be consistent with the wide array of electrocardiographic disturbances reported with the use of paclitaxel. Fortunately, most of the electrocardiographic disturbances associated with paclitaxel appear to be asymptomatic, transient, and tend to resolve spontaneously after discontinuation of the agent. Nevertheless, they often recur when the patient is rechallenged with the drug and therefore may prompt for alternative chemotherapy choices, particularly with presentations such as high-grade AV block or ventricular tachycardia.
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